This trial will test the safety and tolerability of a new cancer drug, and then study how well it works when combined with another cancer drug.
- Solid Tumors, Adult
2 Primary · 3 Secondary · Reporting Duration: Two years
Awards & Highlights
1 Treatment Group
Isunakinra monotherapy and in combination w PD-(L)1 Inhibitor
1 of 1
25 Total Participants · 1 Treatment Group
Primary Treatment: Isunakinra · No Placebo Group · Phase 1 & 2
Who is running the clinical trial?
Age 18+ · All Participants · 0 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
- Hou, Jinzhao, Sharon A. Townson, Joseph T. Kovalchin, Allyson Masci, Olga Kiner, Yanqun Shu, Bracken M. King, et al.. 2013. “Design of a Superior Cytokine Antagonist for Topical Ophthalmic Use”. Proceedings of the National Academy of Sciences. Proceedings of the National Academy of Sciences. doi:10.1073/pnas.1217996110.
- Kovalchin, Joseph, Bracken King, Allyson Masci, Elizabeth Hopkins, Jeremy Fry, Jay Hou, Christian Li, et al.. 2018. “Preclinical Development of EBI-005: An IL-1 Receptor-1 Inhibitor for the Topical Ocular Treatment of Ocular Surface Inflammatory Diseases”. Eye & Contact Lens: Science & Clinical Practice. Ovid Technologies (Wolters Kluwer Health). doi:10.1097/icl.0000000000000414.
- 2020. "Isunakinra Alone and in Combination With a PD-1/PD-L1 Inhibitor in Patients With Solid Tumors". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04121442.
Frequently Asked Questions
Are there vacancies available in this clinical trial?
"According to the data available on clinicaltrials.gov, this experiment is currently enrolling participants and was initially posted in September 2020 with its most recent update occurring on July 2021." - Anonymous Online Contributor
Can you provide a compendium of investigations surrounding Isunakinra?
"Presently, one clinical trial for Isunakinra is actively in progress and none are currently at Phase 3. This research project has a presence in Dallas, Texas with an additional site operating studies." - Anonymous Online Contributor
What is the current capacity of this research study?
"Affirmative. According to clinicaltrials.gov, this medical trial that was first unveiled on September 1st 2020 is currently recruiting patients. 25 volunteers are required from a single site." - Anonymous Online Contributor
Is this venture unprecedented in its methodology?
"At present, Isunakinra is being tested in a single location as part of an ongoing clinical study. This experiment was initiated by Buzzard Pharmaceuticals in 2020 and included 25 participants who successfully completed the Phase 1 & 2 assessment process. 5 additional trials have been conducted since then." - Anonymous Online Contributor